Celso Arango

Celso Arango's AcademicInfluence.com Rankings

Celso Arango

Biology

#3654

World Rank

#5552

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Celso Arango Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Celso Arango is a psychiatrist who has worked as a clinician, researcher, and educator in psychiatry and mental health, notably in the field of child and adolescent psychiatry, psychosis, and mental health promotion.

(See a Problem?)

Celso Arango's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Common variants conferring risk of schizophrenia (2009) (1653)
How mental health care should change as a consequence of the COVID-19 pandemic (2020) (813)
Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group (2017) (423)
Impact of coronavirus syndromes on physical and mental health of health care workers: Systematic review and meta-analysis (2020) (403)
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study (2019) (401)
Mapping genomic loci implicates genes and synaptic biology in schizophrenia (2022) (361)
The continuum of psychotic symptoms in the general population: a cross-national study. (2012) (299)
Cortical and Subcortical Brain Morphometry Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals Across the Lifespan: Results From the ENIGMA ASD Working Group. (2017) (289)
Significance and meaning of neurological signs in schizophrenia: two decades later. (2005) (270)
Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. (2013) (269)
Preventive strategies for mental health. (2018) (268)
The stress and psychological morbidity of the Alzheimer patient caregiver (1999) (250)
Quality of life and disability in patients with obsessive-compulsive disorder (2001) (241)
Negative symptoms of schizophrenia: new developments and unanswered research questions. (2018) (236)
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study (2007) (229)
Violence in inpatients with schizophrenia: a prospective study. (1999) (221)
Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study (2017) (217)
Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. (2020) (213)
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. (2014) (210)
Common variants at VRK2 and TCF4 conferring risk of schizophrenia. (2011) (210)
The impact of COVID-19 lockdown on child and adolescent mental health: systematic review (2021) (200)
Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. (2010) (189)
Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns (2009) (189)
Rates, Distribution, and Implications of Post-zygotic Mosaic Mutations in Autism Spectrum Disorder (2017) (187)
Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. (2016) (171)
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons (2011) (170)
Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort (2010) (169)
Mental health research priorities for Europe. (2015) (160)
Predictors of outcome in early-onset psychosis: a systematic review (2015) (158)
ECNP consensus meeting. Bipolar depression. Nice, March 2007 (2008) (151)
Inflammation in schizophrenia: A question of balance (2015) (146)
Schizophrenia--time to commit to policy change. (2014) (146)
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice (2009) (145)
Treatment of negative symptoms: Where do we stand, and where do we go? (2017) (138)
Progressive brain changes in children and adolescents with first-episode psychosis. (2012) (135)
White matter microstructure correlates of mathematical giftedness and intelligence quotient (2014) (134)
Psychosocial risk factors for suicidality in children and adolescents (2019) (130)
Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. (2018) (129)
Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. (2006) (127)
Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets (2019) (123)
White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder? (2019) (122)
ROAMER: roadmap for mental health research in Europe (2014) (119)
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. (2018) (118)
Prediction of neuropsychological performance by neurological signs in schizophrenia. (1999) (117)
Neurological signs and the heterogeneity of schizophrenia. (2000) (116)
Psychiatry in the aftermath of COVID-19 (2020) (113)
Cannabis and First-Episode Psychosis: Different Long-term Outcomes Depending on Continued or Discontinued Use (2009) (111)
Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study (2019) (106)
Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. (2014) (105)
Early interventions in risk groups for schizophrenia: what are we waiting for? (2016) (104)
Trait and state attributes of insight in first episodes of early-onset schizophrenia and other psychoses: a 2-year longitudinal study. (2011) (101)
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. (2008) (101)
Morphometric assessment of the heteromodal association cortex in schizophrenia. (2004) (101)
Reduced antioxidant defense in early onset first-episode psychosis: a case-control study (2011) (100)
Common variant at 16p11.2 conferring risk of psychosis (2014) (100)
Longitudinal brain changes in early-onset psychosis. (2007) (96)
A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study (2008) (95)
Preventive psychiatry: a blueprint for improving the mental health of young people (2021) (94)
The Human Cerebral Cortex Flattens during Adolescence (2013) (94)
Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey (2013) (93)
The neurobiology of autism spectrum disorders (2014) (92)
Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. (2013) (92)
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes (2003) (92)
The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results (2007) (91)
Pharmacological approaches to treating negative symptoms: A review of clinical trials (2013) (89)
Lessons Learned From the Coronavirus Health Crisis in Madrid, Spain: How COVID-19 Has Changed Our Lives in the Last 2 Weeks (2020) (89)
What is good mental health? A scoping review (2019) (89)
Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study) (2009) (89)
Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. (2020) (89)
Deficit psychopathology and a paradigm shift in schizophrenia research (1999) (86)
Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention. (2020) (86)
The promise of biological markers for treatment response in first-episode psychosis: a systematic review. (2015) (85)
The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms (2004) (85)
Regional gray matter volume deficits in adolescents with first-episode psychosis. (2008) (83)
Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies (2017) (83)
De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia (2019) (82)
Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence (2006) (82)
Neuropsychological functioning in early-onset first-episode psychosis: comparison of diagnostic subgroups (2010) (82)
Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. (2015) (82)
Depression in bipolar disorder versus major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (2012) (81)
Developmental Differences Between Schizophrenia and Bipolar Disorder (2017) (80)
Mathematically gifted adolescents use more extensive and more bilateral areas of the fronto-parietal network than controls during executive functioning and fluid reasoning tasks (2011) (78)
Subcortical Brain Volume, Regional Cortical Thickness, and Cortical Surface Area Across Disorders: Findings From the ENIGMA ADHD, ASD, and OCD Working Groups. (2020) (78)
Olanzapine compared to quetiapine in adolescents with a first psychotic episode (2009) (76)
Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. (2008) (72)
Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis (2017) (70)
Cortical morphology of adolescents with bipolar disorder and with schizophrenia (2014) (68)
Criterios de valoración clínicos y de funcionamiento en un estudio de interacción gen-ambiente en primeros episodios psicóticos (PEPs) (2013) (67)
Does Diagnostic Classification of Early-Onset Psychosis Change Over Follow-Up? (2008) (66)
Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. (2007) (65)
Plasma antioxidant capacity is reduced in Asperger syndrome. (2012) (65)
Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study (2018) (65)
Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion (2020) (64)
A quantitative approach to neuropsychiatry: The why and the how (2017) (63)
Brain morphology and neurological soft signs in adolescents with first-episode psychosis. (2009) (62)
Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome (2020) (62)
Cognitive reserve as a predictor of two year neuropsychological performance in early onset first-episode schizophrenia (2012) (61)
Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. (2014) (61)
Individual differences in the dominance of interhemispheric connections predict cognitive ability beyond sex and brain size (2017) (60)
Association study between obsessive–compulsive disorder and serotonergic candidate genes (2008) (60)
Predictors of suicide attempt in early-onset, first-episode psychoses: a longitudinal 24-month follow-up study. (2013) (59)
DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first‐episode psychosis adolescents (2008) (58)
The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity (2014) (57)
Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: A 2-year longitudinal study (2014) (56)
Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). (2013) (56)
Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives (2015) (56)
Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study (2010) (54)
Progressive brain changes in children and adolescents with early-onset psychosis: A meta-analysis of longitudinal MRI studies (2016) (54)
Autism Spectrum Disorder: Does Neuroimaging Support the DSM-5 Proposal for a Symptom Dyad? A Systematic Review of Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging Studies (2012) (54)
Is attempted suicide different in adolescent and adults? (2008) (54)
Violence among schizophrenia out‐patients compliant with medication: prevalence and associated factors (2009) (53)
Neuropsychological functioning in adolescents with first episode psychosis: A two-year follow-up study (2008) (52)
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. (2010) (52)
Age at First Episode Modulates Diagnosis-Related Structural Brain Abnormalities in Psychosis. (2016) (52)
Cortical structural abnormalities in deficit versus nondeficit schizophrenia (2012) (52)
Progression of brain volume changes in adolescent-onset psychosis. (2009) (51)
Neuropsychological evidence for abnormal neurodevelopment associated with early-onset psychoses (2012) (51)
Two-year diagnostic stability in early-onset first-episode psychosis. (2011) (50)
Can positive family factors be protective against the development of psychosis? (2011) (50)
Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice (2019) (50)
Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice (2019) (50)
Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study (2019) (48)
Risk and protective factors for mental disorders beyond genetics: an evidence‐based atlas (2021) (48)
Gyral and Sulcal Cortical Thinning in Adolescents with First Episode Early-Onset Psychosis (2009) (48)
Detecting schizophrenia at the level of the individual: relative diagnostic value of whole-brain images, connectome-wide functional connectivity and graph-based metrics (2019) (48)
Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study (2012) (47)
Altered white matter microstructure in 22q11.2 deletion syndrome: a multisite diffusion tensor imaging study (2019) (47)
Integrating machining learning and multimodal neuroimaging to detect schizophrenia at the level of the individual (2019) (46)
Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. (1999) (46)
Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia (2007) (46)
Differential role of serotonergic polymorphisms in alcohol and heroin dependence (2009) (45)
Olanzapine effects on auditory sensory gating in schizophrenia. (2003) (45)
Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome (2018) (45)
Longitudinal study of neurological soft signs in first-episode early-onset psychosis. (2012) (45)
Modelling gene-environment interaction in first episodes of psychosis (2017) (45)
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia (2013) (45)
Assessment of School Anti-Bullying Interventions: A Meta-analysis of Randomized Clinical Trials. (2020) (44)
Insight correlates in child- and adolescent-onset first episodes of psychosis: results from the CAFEPS study (2008) (44)
Lessons learned about poor insight. (2011) (44)
Assessment of the increase in variability when combining volumetric data from different scanners (2009) (44)
At issue: stress, hippocampal neuronal turnover, and neuropsychiatric disorders. (2001) (43)
Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder: The ENIGMA adventure (2020) (42)
Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey. (2011) (42)
Psychopathology in Children and Adolescents with ASD Without Mental Retardation (2013) (41)
The effect of quetiapine on aggression and hostility in patients with schizophrenia (2005) (41)
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics (2017) (41)
Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis (2020) (41)
Clinical effectiveness of new generation antipsychotics in adolescent patients (2004) (40)
Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. (2019) (40)
Early intervention in psychosis: From clinical intervention to health system implementation (2018) (39)
Cognitive Functioning in Children and Adolescents in Their First Episode of Psychosis: Differences Between Previous Cannabis Users and Nonusers (2010) (39)
Neurological soft signs in adolescents with first episode psychosis (2006) (39)
Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study (2014) (39)
Randomized trial of omega-3 for autism spectrum disorders: Effect on cell membrane composition and behavior (2017) (39)
Structural neuroimaging in adolescents with a first psychotic episode. (2005) (39)
Specialty Care Programme for Autism Spectrum Disorders in an Urban Population: A Case-Management Model for Health Care Delivery in an asd Population (2013) (39)
Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case–control study (2020) (39)
Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. (2011) (38)
The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study (2016) (38)
Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure (2018) (38)
Improving quality at the hospital psychiatric ward level through the use of the EFQM model. (2007) (37)
Antidepressants in child and adolescent depression: where are the bugs? (2007) (37)
Neuropsychological correlates of P50 sensory gating in patients with schizophrenia (2013) (36)
Predictors of schizophrenia spectrum disorders in early-onset first episodes of psychosis: a support vector machine model (2015) (36)
Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case–control sample from Spain (2014) (36)
Assessing clinical and functional outcomes in a gene–environment interaction study in first episode of psychosis (PEPs) (2013) (36)
BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents (2016) (36)
Managing acute exacerbations of schizophrenia: focus on quetiapine (2004) (35)
Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. (2000) (35)
The Relationship Between White Matter Microstructure and General Cognitive Ability in Patients With Schizophrenia and Healthy Participants in the ENIGMA Consortium. (2020) (35)
Reduced Gyrification Is Related to Reduced Interhemispheric Connectivity in Autism Spectrum Disorders. (2015) (35)
Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis (2019) (34)
Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study (2019) (34)
LA PSIQUIATRÍA EN LAS SECUELAS DE COVID-19 (2020) (34)
CIBERSAM: Ten years of collaborative translational research in mental disorders. (2019) (34)
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. (2015) (34)
Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. (2016) (33)
P50 gating in deficit and nondeficit schizophrenia (2010) (33)
Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. (2015) (33)
Multicenter study of brain volume abnormalities in children and adolescent-onset psychosis. (2011) (33)
European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP) (2019) (33)
Antipsychotic Use in Children and Adolescents: A 1-Year Follow-Up Study (2014) (33)
The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme (2020) (33)
Placebo effect in child and adolescent psychiatric trials (2012) (33)
Neurological soft signs in adolescents with first episode psychosis: Two-year followup (2008) (32)
Intervention for adolescents with early-onset psychosis and their families: a randomized controlled trial. (2014) (32)
Diez años de investigación traslacional colaborativa en enfermedades mentales: el CIBERSAM (2019) (32)
A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis (2014) (32)
Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the Positive and Negative Syndrome Scale. (2010) (31)
Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry (2011) (31)
Validation of a European Spanish-version of the University of California performance Skills Assessment (Sp-UPSA) in patients with schizophrenia and bipolar disorder (2013) (31)
The Association Between Comorbid Autism Spectrum Disorders and Antipsychotic Treatment Failure in Early-Onset Psychosis: A Historical Cohort Study Using Electronic Health Records. (2017) (31)
Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study (2012) (31)
Polypharmacy with antidepressants in children and adolescents. (2014) (31)
Findings of proton magnetic resonance spectometry in the dorsolateral prefrontal cortex in adolescents with first episodes of psychosis (2007) (31)
Association between the A-1438G polymorphism of the serotonin 2A receptor gene and nonimpulsive suicide attempts (2008) (30)
Cuando la asistencia no sigue a la evidencia: el caso de la falta de programas de intervención temprana en psicosis en España (2017) (30)
Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study (2008) (29)
Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia (2008) (29)
Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit (2020) (29)
Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis (2019) (28)
Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study (2011) (28)
Dysbindin‐1 gene contributes differentially to early‐ and adult‐onset forms of functional psychosis (2011) (28)
The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey (2020) (28)
Regional specificity of thalamic volume deficits in male adolescents with early-onset psychosis (2012) (28)
The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the present (2021) (27)
Premorbid impairments in early-onset psychosis: Differences between patients with schizophrenia and bipolar disorder (2013) (27)
Progressive brain changes in schizophrenia. (2007) (27)
Cysticercosis in chronic psychiatric inpatients from a Venezuelan community. (2005) (27)
Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance (2016) (27)
Genetic variants associated with longitudinal changes in brain structure across the lifespan (2021) (27)
Neurological soft signs in juvenile patients with Asperger syndrome, early‐onset psychosis, and healthy controls (2010) (27)
Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study (2019) (27)
Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis (2020) (27)
The affective dimension of early-onset psychosis and its relationship with suicide. (2015) (26)
Neurological Adverse Effects of Antipsychotics in Children and Adolescents (2015) (26)
Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis. (2011) (26)
Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History (2016) (26)
Consenso español sobre los riesgos y detección de la hiperprolactinemia iatrogénica por antipsicóticos (2016) (25)
Assessment Tools for Soft Signs (2003) (25)
Oxidative/Nitrosative stress in psychiatric disorders: are we there yet? (2014) (25)
Insular pathology in young people with high-functioning autism and first-episode psychosis (2017) (25)
Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study (2020) (24)
Sensory-to-Cognitive Systems Integration Is Associated With Clinical Severity in Autism Spectrum Disorder. (2020) (24)
Mental health services during the first wave of the COVID-19 pandemic in Europe: Results from the EPA Ambassadors Survey and implications for clinical practice (2021) (24)
Psychopathological sequelae of the 11 March terrorist attacks in Madrid (2007) (24)
The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. (2016) (23)
Association between Heroin Dependence and 5-HT2A Receptor Gene Polymorphisms (2008) (23)
Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges (2013) (23)
Working definitions, subjective and objective assessments and experimental paradigms in a study exploring social withdrawal in schizophrenia and Alzheimer’s disease (2019) (22)
Interactions between functional serotonergic polymorphisms and demographic factors influence personality traits in healthy Spanish Caucasians (2010) (22)
Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis (2015) (21)
Role of serotonergic-related systems in suicidal behavior: Data from a case–control association study (2011) (21)
Twenty-Four Months of Antipsychotic Treatment in Children and Adolescents With First Psychotic Episode: Discontinuation and Tolerability (2013) (21)
High degree of tolerability for monotherapy with high doses of quetiapine: a case report. (2002) (21)
Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate (2019) (21)
Polymorphisms of the IL-1 gene complex are associated with alcohol dependence in Spanish Caucasians: data from an association study. (2009) (21)
Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning (2020) (20)
Estimation of the Intelligence Quotient Using Wechsler Intelligence Scales in Children and Adolescents with Asperger Syndrome (2012) (20)
Association between relative temporal and prefrontal sulcal cerebrospinal fluid and illness duration in schizophrenia (2002) (20)
Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer’s disease (2019) (20)
A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders (2021) (20)
Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis (2019) (20)
Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: design of a follow-up protocol and baseline results. (2012) (20)
Antipsychotic effects on auditory sensory gating in schizophrenia patients (2009) (20)
Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study (2017) (19)
Practitioner review: Long-term pharmacological treatment of pediatric bipolar disorder. (2014) (19)
The Schizophrenia Construct: Symptomatic Presentation (2011) (19)
Executive function is affected in autism spectrum disorder, but does not correlate with intelligence. (2016) (19)
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions (2021) (19)
Present and future of developmental neuropsychopharmacology (2015) (19)
Psychotic-like experiences, polygenic risk scores for schizophrenia, and structural properties of the salience, default mode, and central-executive networks in healthy participants from UK Biobank (2019) (19)
Psychoeducational Group Intervention for Adolescents With Psychosis and Their Families: A Two-Year Follow-Up. (2015) (19)
One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry. (2019) (19)
Intracranial and subcortical volumes in adolescents with early‐onset psychosis: A multisite mega‐analysis from the ENIGMA consortium (2020) (18)
Predictors of functional and clinical outcome in early-onset first-episode psychosis: the child and adolescent first episode of psychosis (CAFEPS) study. (2015) (18)
Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: a systematic review and meta-analysis (2017) (18)
Gray matter changes and cognitive predictors of 2-year follow-up abnormalities in early-onset first-episode psychosis (2017) (17)
Una década del proyecto de primeros episodios psicóticos (PEPs): avanzando hacia una psiquiatría de precisión (2019) (17)
Risperidone administered during adolescence induced metabolic, anatomical and inflammatory/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model (2019) (17)
When the healthcare does not follow the evidence: The case of the lack of early intervention programs for psychosis in Spain. (2017) (17)
The lived experience of psychosis: a bottom‐up review co‐written by experts by experience and academics (2022) (17)
Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas (2021) (17)
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. (2021) (17)
Aggression subtypes relate to distinct resting state functional connectivity in children and adolescents with disruptive behavior (2018) (17)
Dynamics of Brain Structure and its Genetic Architecture over the Lifespan (2020) (16)
Effects of copy number variations on brain structure and risk for psychiatric illness: Large‐scale studies from the ENIGMA working groups on CNVs (2021) (16)
Universal and Selective Interventions to Prevent Poor Mental Health Outcomes in Young People: Systematic Review and Meta-analysis (2021) (16)
Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer (2018) (16)
Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study (2021) (16)
A framework for assessing neuropsychiatric phenotypes by using smartphone-based location data (2020) (16)
Interleukin‐1 Gene Complex in Schizophrenia: An Association Study * (2006) (16)
Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis (2022) (16)
Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis (2021) (15)
Primary prevention of depression: An umbrella review of controlled interventions. (2021) (15)
Functional Magnetic Resonance Imaging Connectivity Accurately Distinguishes Cases With Psychotic Disorders From Healthy Controls, Based on Cortical Features Associated With Brain Network Development. (2020) (15)
Subtly altered topological asymmetry of brain structural covariance networks in autism spectrum disorder across 43 datasets from the ENIGMA consortium (2021) (15)
A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia (2007) (15)
Posttraumatic stress disorder in victims of the March 11 attacks in Madrid admitted to a hospital emergency room: 6-month follow-up (2006) (15)
Subcortical brain volume, regional cortical thickness and cortical surface area across attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) (2019) (15)
QTc changes after 6 months of second-generation antipsychotic treatment in children and adolescents. (2008) (15)
Novel genes and sex differences in COVID-19 severity (2022) (14)
Cortical morphometry in frontoparietal and default mode networks in math‐gifted adolescents (2016) (14)
Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. (2019) (14)
Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis (2019) (14)
Personality organization and its association with clinical and functional features in borderline personality disorder (2017) (14)
Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings (2021) (14)
Nonverbal Delayed Recognition in the Relatives of Schizophrenia Patients With or Without Schizophrenia Spectrum (2008) (13)
Antipsicóticos inyectables de liberación prolongada para el tratamiento de la esquizofrenia en España (2019) (13)
Cognition and functionality in delusional disorder (2019) (13)
Mobile App–Based Intervention for Adolescents With First-Episode Psychosis: Study Protocol for a Pilot Randomized Controlled Trial (2019) (13)
Gene-environment interaction as a predictor of early adjustment in first episode psychosis (2017) (12)
The Madrid Declaration: why we need a coordinated Europe-wide effort in mental health research (2011) (12)
Candidate gene associations studies in psychiatry: time to move forward (2017) (12)
Efectos secundarios del tratamiento antipsicótico en niños y adolescentes naïve o quasi-naïve: diseño de un protocolo de seguimiento y resultados basales (2012) (12)
La función ejecutiva está alterada en los trastornos del espectro autista, pero esta no correlaciona con la inteligencia (2016) (12)
Self-Perceived Needs Are Related to Violent Behavior Among Schizophrenia Outpatients (2011) (12)
Risk and protective factors for mental disorders with onset in childhood/adolescence: An umbrella review of published meta-analyses of observational longitudinal studies (2020) (12)
Adaptación y validación en castellano del Inventario para la Esquizofrenia Deficitaria (2007) (12)
Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking (2017) (12)
Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium (2022) (12)
The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings From the Multinational EU-GEI Study. (2021) (11)
Efficacy and safety of adjunctive bitopertin (5 and 10mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the phase III DayLyte study (2014) (11)
A Multimodality Workstation In Practice (1999) (11)
Association study of the interleukin-1 gene complex and tumor necrosis factor alpha gene with suicide attempts (2008) (11)
Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. (2019) (11)
Obstetric complications as a risk factor for first psychotic episodes in childhood and adolescence (2009) (11)
Digital health technologies in clinical trials for central nervous system drugs: an EU regulatory perspective (2020) (11)
Development and psychometric properties of the Suicidality: Treatment Occurring in Paediatrics (STOP) Suicidality Assessment Scale (STOP-SAS) in children and adolescents (2016) (11)
Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study (2021) (11)
Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the Phase III FlashLyte Study (2014) (11)
Investigación en salud mental en España: algo más que brotes verdes (2012) (10)
Migration history and risk of psychosis: results from the multinational EU-GEI study (2021) (10)
Genetic underpinnings of sociability in the general population (2021) (10)
Specific cortical and subcortical alterations for reactive and proactive aggression in children and adolescents with disruptive behavior (2020) (10)
Distinct associations between fronto-striatal glutamate concentrations and callous-unemotional traits and proactive aggression in disruptive behavior (2019) (10)
Attitude toward antipsychotic medication as a predictor of antipsychotic treatment discontinuation in first-episode early-onset psychosis. (2008) (10)
Características diferenciales de eficacia y tolerabilidad de los antipsicóticos de segunda generación en el tratamiento de trastornos psicóticos en niños y adolescentes (2010) (10)
Cognition in schizophrenia: Summary Nice Consultation Meeting 2012 (2013) (10)
A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs. (2013) (10)
Atypical age-dependency of executive function and white matter microstructure in children and adolescents with autism spectrum disorders (2017) (10)
10Kin1day: A Bottom-Up Neuroimaging Initiative (2019) (10)
Ethical considerations for precision psychiatry: A roadmap for research and clinical practice (2022) (9)
Child and adolescent neuropsychopharmacology: Now or never (2011) (9)
Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra (2014) (9)
Psychiatric comorbidities in Asperger syndrome are related with polygenic overlap and differ from other Autism subtypes (2020) (9)
Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review (2022) (9)
CIBERSAM: Ten years of collaborative translational research in mental disorders (2019) (9)
EFFICACY AND SAFETY OF ADJUNCTIVE BITOPERTIN VERSUS PLACEBO IN SUBJECTS WITH PERSISTENT PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS – UPDATE FROM THE SEARCHLYTE PROGRAMME (2014) (9)
One-Year Prospective Study of Liver Function Tests in Children and Adolescents on Second-Generation Antipsychotics: Is There a Link with Metabolic Syndrome? (2018) (8)
Virtual Ontogeny of Cortical Growth Preceding Mental Illness (2022) (8)
Graph Convolutional Networks Reveal Network-Level Functional Dysconnectivity in Schizophrenia (2022) (8)
First-Episode Psychosis Research: Time to Move Forward (by Looking Backwards). (2015) (8)
Executive functioning and emotion recognition in youth with oppositional defiant disorder and/or conduct disorder (2020) (8)
Subgrouping children and adolescents with disruptive behaviors: symptom profiles and the role of callous–unemotional traits (2020) (8)
Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway (2020) (8)
A normative chart for cognitive development in a genetically selected population (2021) (8)
The effects of callous-unemotional traits and aggression subtypes on amygdala activity in response to negative faces (2020) (8)
Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study (2019) (8)
The complex association between the antioxidant defense system and clinical status in early psychosis (2018) (8)
Sibutramine for compulsive eating in hypothalamic deficiency. (2002) (8)
A developmental approach to dimensional expression of psychopathology in child and adolescent offspring of parents with bipolar disorder (2017) (8)
Calling for the integration of children's mental health and protection into COVID-19 responses (2021) (8)
Actitud respecto a la medicación antipsicótica como factor predictivo de la suspensión del tratamiento antipsicótico en el período inicial de la psicosis de inicio temprano (2008) (8)
Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of First Episode Psychosis patients and controls (2019) (8)
Going beyond "trial-and-error" in psychiatric treatments: OPTiMiSE-ing the treatment of first episode of schizophrenia. (2015) (7)
[Adaptation and validation into Spanish of Schedule for the Deficit Syndrome]. (2007) (7)
Gambling Dual Disorder: A Dual Disorder and Clinical Neuroscience Perspective (2020) (7)
Someone is not listening to the facts: there is little psychiatry outside child and adolescent psychiatry (2012) (7)
Lack of association between endothelial nitric oxide synthase (NOS3) gene polymorphisms and suicide attempts (2007) (7)
The independent and combined influence of schizophrenia polygenic risk score and heavy cannabis use on risk for psychotic disorder: A case-control analysis from the EUGEI study (2019) (7)
Neuroanatomical deficits shared by youth with autism spectrum disorders and psychotic disorders (2019) (7)
N-acetyltransferase-2 polymorphisms and schizophrenia (2006) (7)
Prevalence of premorbid personality disorder and its clinical correlates in patients with delusional disorder (2013) (7)
The interplay between functioning problems and symptoms in first episode of psychosis: An approach from network analysis. (2021) (7)
Should psychiatry deal only with mental disorders without an identified medical aetiology? (2016) (7)
Dissimilarity in sulcal width patterns in the cortex can be used to identify patients with schizophrenia with extreme deficits in cognitive performance (2020) (7)
The state of psychiatry in Spain (2012) (7)
PIENSA: Development of an Early Intervention Program for Adolescents With Early-Onset Psychosis and Their Families (2012) (7)
Absence of Change in Corrected QT Interval in Children and Adolescents Receiving Antipsychotic Treatment: A 12 Month Study. (2016) (7)
Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia – data from the OPTiMiSE trial (2020) (7)
Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study. (2020) (6)
Desarrollo profesional en investigación traslacional en neurociencias y salud mental: educación y formación dentro del Centro de Investigación Biomédica en Red en Salud Mental (2015) (6)
Psychiatry in the aftermath of COVID-19 (2020) (6)
Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial (2020) (6)
Mental health care and COVID-19 (2020) (6)
Omega-3 fatty acids during adolescence prevent schizophrenia-related behavioural deficits: Neurophysiological evidences from the prenatal viral infection with PolyI:C (2021) (6)
The enduring gap in educational attainment in schizophrenia according to the past 50 years of published research: a systematic review and meta-analysis. (2022) (6)
Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients. (2020) (6)
Pre-training inter-rater reliability of clinical instruments in an international psychosis research project (2020) (6)
Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders (2021) (6)
Demographic and Clinical Characteristics, Including Subsyndromal Symptoms Across Bipolar-Spectrum Disorders in Adolescents. (2020) (6)
A replication study of JTC bias, genetic liability for psychosis and delusional ideation (2020) (6)
Physical comorbidity in mental illness in paediatric population: need for an integrated health care approach to paediatrics and child psychiatry (2011) (6)
Desarrollo de la versión española de la Escala Breve para la Evaluación de la Capacidad Funcional [Sp-UPSA-Brief] para pacientes con esquizofrenia y trastorno bipolar (2014) (6)
Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence (2022) (6)
Gender effects on brain changes in early-onset psychosis (2015) (6)
Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. (2017) (6)
Altered structural brain asymmetry in autism spectrum disorder: large-scale analysis via the ENIGMA Consortium (2019) (6)
Un tratamiento integral para el trastorno por déficit de atención e hiperactividad en toda Europa (2015) (5)
Fármacos antidepresivos en el tratamiento de la cefalea tensional (2008) (5)
Mental Health Research in Spain: a bit more than green shoots. (2012) (5)
DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders (2020) (5)
Sex differences in lifespan trajectories and variability of human sulcal and gyral morphology (2020) (5)
Genetic underpinnings of sociability in the UK Biobank (2019) (5)
The need for paediatric registries to assess long-term brain effects of psychotropic medications: The case of bipolar disorder (2018) (5)
Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case−control study (2021) (5)
[Development of the Spanish brief-version of the University of California Performance Skills Assessment (Sp-UPSA-Brief) in patients with schizophrenia and bipolar disorder]. (2014) (5)
The association between gene variants and longitudinal structural brain changes in psychosis: a systematic review of longitudinal neuroimaging genetics studies (2017) (5)
Needs of people with psychosis and their caregivers: «In their own voice». (2020) (5)
The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study (2022) (5)
Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium (2022) (5)
Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study (2021) (5)
[The deficit syndrome: a domain of schizophrenia]. (1998) (5)
Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries (2021) (5)
Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder (2018) (5)
Elevated Extracellular Free-Water in a Multicentric First-Episode Psychosis Sample, Decrease During the First 2 Years of Illness. (2020) (5)
The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis (2021) (5)
Leukocyte telomere length in patients with schizophrenia and related disorders: a meta-analysis of case-control studies (2022) (4)
Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI). (2022) (4)
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1 (2021) (4)
The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study (2021) (4)
Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study (2021) (4)
The search for an autoimmune origin of psychotic disorders: Prevalence of autoantibodies against hippocampus antigens, glutamic acid decarboxylase and nuclear antigens (2021) (4)
Reactive/proactive aggression specific cortical and subcortical alterations in children and adolescents with disruptive behavior (2018) (4)
Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder (2021) (4)
Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents (2010) (4)
Structural magnetic resonance imaging data do not help support DSM-5 autism spectrum disorder category (2013) (4)
Moving interventions from after to before diagnosis (2017) (4)
The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study (2021) (4)
Calling for the integration of children's mental health and protection into COVID-19 responses (2021) (4)
Risk factors for respiratory disease in chronic psychiatric in patients (2007) (4)
Authors' reply to ‘on the existence of a linguistic distance in schizophrenia’ (2020) (4)
To treat or not to treat? and How to treat? Two questions whose answers are far removed from evidence informed practice in child psychiatry (2013) (4)
The effects of callous-unemotional traits and aggression subtypes on amygdala activity in response to negative faces – ERRATUM (2020) (4)
Development and psychometric properties of the “Suicidality: Treatment Occurring in Paediatrics (STOP) Risk and Resilience Factors Scales” in adolescents (2019) (4)
Reconceptualising treatment-resistant depression as difficult-to-treat depression. (2021) (4)
Antioxidant defense system and family environment in adolescents with family history of psychosis (2012) (4)
Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia (2022) (4)
Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study (2021) (3)
Analyses of rare and common alleles in parent-proband trios implicate rare missense variants in SLC6A1 in schizophrenia and confirm the involvement of loss of function intolerant and neurodevelopmental disorder genes (2019) (3)
In vivo white matter microstructure in adolescents with early-onset psychosis: a multi-site mega-analysis (2022) (3)
Management of acutely ill patients in the hospital setting: focus on quetiapine (2007) (3)
The genetic contribution to first psychotic episodes in children and adolescents of the child and adolescent first-episode psychosis study. (2008) (3)
Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain (2019) (3)
Predictors of suicide attempt in early-onset, first-episode psychoses (2012) (3)
The role of depression in the prediction of a “late” remission in first-episode psychosis: An analysis of the OPTiMiSE study (2021) (3)
Clinical subtyping and early detection: short-term challenges for child and adolescent psychiatry (2010) (3)
Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): rationale, objectives, design and sample description. (2014) (3)
Age at first episode modulates diagnosis-related structurals brain abnormalities in patients with first-episode psychosis. (2016) (3)
One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry (2019) (3)
Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study. (2022) (3)
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs (2022) (3)
A polygenic approach to the association between smoking and schizophrenia (2021) (3)
Correction: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study (2019) (3)
Exploring the biological role of postzygotic and germinal de novo mutations in ASD (2021) (3)
Psychometric properties of the Spanish version of the Diagnostic Interview for Depressive Personality (2012) (3)
P.7.a.009 Predictors of diagnosis of nonaffective acute remitting psychosis in patients with early-onset first episodes of psychosis (2012) (3)
Age-related brain deviations and aggression. (2022) (3)
Reward and Punishment Sensitivity are Associated with Cross-disorder Traits (2021) (3)
Fronto-Parietal Gray Matter Volume Loss Is Associated with Decreased Working Memory Performance in Adolescents with a First Episode of Psychosis (2021) (3)
Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study. (2022) (3)
P.3.a.025 Open-label randomized trial comparing the efficacy and tolerability of quetiapine and olanzapine in first episode psychosis in adolescents (2006) (3)
Necesidades de las personas con psicosis y sus cuidadores: «en voz propia» (2020) (3)
Efficacy of a Web-Enabled, School-Based, Preventative Intervention to Reduce Bullying and Improve Mental Health in Children and Adolescents: Study Protocol for a Cluster Randomized Controlled Trial (2021) (3)
Calidad de vida y discapacidad en pacientes con trastorno obsesivo-compulsivo (2001) (3)
Development of an early intervention programme for adolescents with emotion dysregulation and their families: Actions for the treatment of adolescent personality (ATraPA) (2020) (3)
A longitudinal comparison of two neurocognitive test batteries in patients with schizophrenia and healthy volunteers: Time effects on neuropsychological performance and their relation to functional outcome (2019) (3)
Explorer 10 Kin 1 day : A Bottom-Up Neuroimaging Initiative (2019) (3)
Reply to: Another Vision From the Coronavirus Health Crisis in Spain: The Perspective From the Plena inclusión Developmental Disabilities Associative Movement (2020) (2)
Needs of people with psychosis and their caregivers: “In their own voice” (2020) (2)
P.3.a.032 Cognitive efficacy of quetiapine and olanzapine in early onset first episode psychosis (2006) (2)
Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description (2014) (2)
When the healthcare does not follow the evidence: The case of the lack of early intervention programs for psychosis in Spain (2017) (2)
P.2.139 Antipsychotic treatment adherence andviolence in schizophrenia outpatients: A randomized prospective trial (2004) (2)
S.17.03 Double-blind crossed-over randomized controlled-trial with omega-3 fatty acids for autism spectrum disorders (2015) (2)
Psychiatrists are experts when it comes to missing boats. Will prevention be the next one? (2019) (2)
Building up resilience in an uncertain world: mental health challenges in the aftermath of the first modern pandemic (2021) (2)
Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response. (2022) (2)
31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS (2018) (2)
Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study (2021) (2)
Building up careers in translational neuroscience and mental health research: Education and training in the Centre for Biomedical Research in Mental Health☆ (2015) (2)
Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study. (2022) (2)
A integral treatment for attention deficit hyperactivity disorder in Europe. (2015) (2)
Informe del 3.er Foro sobre Políticas de Actuación del Consejo Europeo del Cerebro (2011) (2)
More treatment for those most in need? A foregone conclusion? (2015) (2)
ANTIPSYCHOTICS EFFECTS ON AUDITORY SENSORY GATING IN SCHIZOPHRENIA (2008) (2)
Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and alzheimer’s disease patients (2022) (2)
Affective symptom dimensions in early-onset psychosis over time: a principal component factor analysis of the Young Mania Rating Scale and the Hamilton Depression Rating Scale (2021) (2)
Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza (2011) (2)
Longitudinal course of cognition in schizophrenia (2009) (2)
Validation of the Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) questionnaire for adults (2022) (1)
The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications (2023) (1)
The relationship between negative symptoms, social cognition, and social functioning in patients with first episode psychosis. (2022) (1)
First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data (2022) (1)
[Patient care, right to information and consent for minors in situations of parental conflict. Clinical guidelines in the context of Spanish legislation]. (2020) (1)
Child neuropsychopharmacology: good news… the glass is half full (2013) (1)
[Schizophrenia: a brain disease. I. Structural neuroimaging]. (1999) (1)
Understanding the Influence of Personality Traits on Risk of Suicidal Behaviour in Schizophrenia Spectrum Disorders: A Systematic Review (2021) (1)
Modulación de alteraciones prefrontales por el polimorfismo COMT Val158Met en primeros episodios psicóticos (2021) (1)
Tratamiento con quetiapina en adolescentes: estudio naturalstico de 6 meses de seguimiento (2010) (1)
Science and fashion: inflammation and oxidative stress in psychiatry (2018) (1)
Corrigendum to “Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. [European Neuropsychopharmacology Volume 48, July 2021, Pages 3-31]” (2021) (1)
P.7.c.003 Obesogenic capacity of second-generation antipsychotics in naïve-adolescents and their impact on leptin, adiponectin and ghrelin (2011) (1)
P.3.004 Risk for adverse health outcome in antipsychotic-naïve adolescents after 12 months of treatment with second-generation antipsychotics (2011) (1)
P.690 Impact of second-generation antipsychotic side effects on functioning from a schizophrenia patient perspective: European perspective of a global patient-centered survey (2019) (1)
Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study (2022) (1)
University of Groningen Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples Genetic Risk and Outcome of Psychosis (2020) (1)
[Schizophrenia: a brain disease. II. Functional neuroimaging]. (2000) (1)
Family psycho-education in early onset psychosis: Effects on relapse and on the use of clinical services after the first psychotic episode (Results derived from the PIENSA program) (2012) (1)
P.7.d.016 Are children treated with second-generation antipsychotics at higher risk of weight gain than adults? (2016) (1)
Functional MRI connectivity accurately distinguishes cases with psychotic disorders from healthy controls, based on cortical features associated with neurodevelopment (2019) (1)
Development of the Spanish Brief-version of the University of California Performance Skills Assessment (Sp-UPSA-Brief) in patients with schizophrenia and bipolar disorder (2014) (1)
Building up careers in translational neuroscience and mental health research: Education and training in the Centre for Biomedical Research in Mental Health. (2015) (1)
Genes and impulsivity: comment to the study of Nomura et al. on “Involvement of a polymorphism in the 5-HT2A receptor gene in impulsive behavior. Psychopharmacology 187:30-35 (2006) (1)
How does neighbourhood socio-economic status affect the interrelationships between functioning dimensions in first episode of psychosis? A network analysis approach. (2021) (1)
Unraveling the relationship of loneliness and isolation in schizophrenia: Polygenic dissection and causal inference. (2020) (1)
The bipolar–depressive continuum in the National Epidemiologic Survey on Alcohol and Related Conditions (2013) (1)
Scalability of the Positive and Negative Syndrome Scale in first‐episode schizophrenia assessed by Rasch models (2022) (1)
Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case–Control Study (2022) (1)
Cortical thinning over two years after first-episode psychosis depends on age of onset (2022) (1)
Humanization in mental health plans in Spain. (2021) (1)
Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study (2023) (1)
Clinical decision-making style preferences of European psychiatrists: Results from the Ambassadors survey in 38 countries (2022) (1)
Role of Executive Function in Response to a Problem Solving Based Psychoeducational Intervention in Adolescents with Psychosis: The PIENSA Trial Revisited (2019) (1)
Fluoxetine as an add-on medication to typical antipsychotics in chronic schizophrenia (2000) (1)
The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations (2022) (1)
Bridging Big Data: Procedures for Combining Non-equivalent Cognitive Measures from the ENIGMA Consortium (2023) (1)
P.7.b.013 Safety of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study (2017) (0)
P.3.c.049 Risk of adverse health outcome and metabolic syndrome in adolescents treated with antipsychotics: preliminary results (2011) (0)
Persistence of negative symptoms in psychotic patients: Results from the CLAMORS study (2007) (0)
ANTIOXIDANT STATUS IN FIRST EPISODES OF EARLY ONSET PSYCHOSIS COMPARED WITH ASPERGER AND HEALTHY CONTROL ADOLESCENTS (2010) (0)
ASSOCIATION STUDY OF ENDOTHELIAL NITRIC OXIDE SYNTHASE (NOS3) POLYMORPHISMS AND SCHIZOPHRENIA (2008) (0)
GENETIC VARIABILITY IN DYSBINDIN-1 GENE (DTNBP1) CONTRIBUTES DIFFERENTIALLY TO EARLY AND ADULT ONSET FUNCTIONAL PSYCHOSES AND IT IS ASSOCIATED WITH THE FAMILIAL TRANSMISSION OF IQ AND PREFRONTAL COGNITIVE DEFICITS (2010) (0)
Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery (2023) (0)
17. THE OPTiMISE STUDY: AMISULPRIDE AND OLANZAPINE FOLLOWED BY OPEN-LABEL TREATMENT WITH CLOZAPINE IN FIRST-EPISODE SCHIZOPHRENIA (2019) (0)
P.1.016 Role of leptin and adiponectin in weight gain related to second-generation antipsychotics (2014) (0)
Drug development in ASD, an ISCTM-ECNP joint adventure (2021) (0)
P.3.d.068 Short-term weight gain in antipsychotic-naïve pediatric and adult patients with psychosis treated with second-generation antipsychotics (2016) (0)
P 50 gating in de fi cit and nonde fi cit schizophrenia (2010) (0)
T117. FUNCTIONAL TRAJECTORY IN FIRST-EPISODE PSYCHOSIS BASED ON PREMORBID IQ AND AGE OF ONSET (2019) (0)
Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy. (2023) (0)
Morphometric similarity across the life span: A longitudinal study (2019) (0)
31. OPTIMISE-ING THE TREATMENT OF FIRST-EPISODE SCHIZOPHRENIA (2018) (0)
P-18. Poster session: Psychotic disorders IV (2005) (0)
Poster #60 COGNITIVE RESERVE AS A PREDICTOR OF TWO YEAR NEUROPSYCHOLOGICAL PERFORMANCE IN EARLY ONSET FIRST-EPISODE SCHIZOPHRENIA (2012) (0)
Social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis (2021) (0)
P.7.c.004 Metabolic side effects in children and adolescents treated with second-generation antipsychotics (2008) (0)
Neuropsychological functioning in early-onset first-episode psychosis: lack of differences among diagnostic subgroups (2007) (0)
PP181 METABOLIC RISK IN ADOLESCENTS TREATED WITH ATYPICAL ANTIPSYCHOTIC DRUGS (2010) (0)
P.7.b.008 Progressive loss of gray matter volume in the frontal lobe is associated with decreased working memory performance over time in adolescent psychosis (2015) (0)
[Quetiapine treatment in adolescents: A 6-month naturalistic study]. (2010) (0)
Poster #255 LONGITUDINAL STUDY OF NEUROLOGICAL SOFT SIGNS IN FIRST EPISODE EARLY ONSET PSYCHOSIS (2012) (0)
P.7.b.009 Predictors of weight gain after six months of treatment with second-generation antipsychotics in pediatric and adult patients (2014) (0)
The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study. (2023) (0)
S.21.02 Efficacy and safety of antipsychotics in early onset psychosis (2009) (0)
ME1 Treatment of schizophrenia (2009) (0)
FRONTAL CORTICAL THICKNESS IS ASSOCIATED WITH CLINICAL IMPROVEMENT OF NEGATIVE SYMPTOMS IN MALE ADOLESCENTS WITH EARLY-ONSET FIRST-EPISODE PSYCHOSIS (2010) (0)
SU53. Needs of Young People With Schizophrenia/Psychosis and Their Caregivers: A Large-Scale Survey (2017) (0)
Quality of care in psychiatry is related to research activity (2021) (0)
A Collaborative Evaluation Form for Use in the Acute Care Burn Center: 204. (2001) (0)
P.172 Preliminary fMRI results exploring brain activity in a spatial navigation task in schizophrenia, Alzheimer's Disease, and healthy controls (2019) (0)
Schizophrenia polygenic risk score and cannabis use modify psychosis expression in first episode psychosis patients and population controls (2019) (0)
T75. Amygdala and Ventral Striatum Volume and its Association With Subtypes of Aggression (2018) (0)
Comparison of the subjective response to typical neuroleptics, tisperidone and olazapine in schizophrenia (1998) (0)
T115. TARGETING NICOTINIC AND NMDA RECEPTORS CONCURRENTLY: ROCKET SCIENCE, COMMON SENSE OR GAME CHANGER? (2019) (0)
50DE NOVO LOF AND DAMAGING MISSENSE VARIANTS ASSOCIATED WITH SCHIZOPHRENIA ARE CONCENTRATED IN LOF INTOLERANT GENES (2019) (0)
P.389 Social withdrawal levels influence cerebellar activity during consumption of monetary rewards – fMRI results from the PRISM clinical study (2020) (0)
P.4.029 Antioxidant status and fatty acids in adolescents with Asperger syndrome and first episodes of early-onset psychosis (2013) (0)
S.01.03 Treatment of bipolar disorders in children and adolescents (2009) (0)
University of Groningen The role of depression in the prediction of a "late" remission in first-episode psychosis (2021) (0)
T84COMMON PREDISPOSING VARIATION TO SCHIZOPHRENIA IS SUBJECTED TO RECENT NATURAL SELECTION BY DECREASING ALLELE FREQUENCY IN EUROPEAN POPULATIONS (2019) (0)
Is there such a thing as gambling dual disorder? Preliminary evidence and clinical profiles (2022) (0)
Different Whole-Brain Functional Connectivity Correlates of Reactive-Proactive Aggression and Callous-Unemotional Traits in Disruptive Children and Adolescents (2019) (0)
TH77. APPLYING POLYGENIC SCORING OF SEVERE MENTAL DISORDERS TO TEST SHARED VULNERABILITY AND RISK PREDICTION IN PSYCHOTIC DISORDERS (2021) (0)
749 Subjective response to neuroleptics in schizophrenia (1997) (0)
P.484 Preliminary fMRI results exploring processing of monetary and social rewards in schizophrenia, Alzheimer's disease, and healthy controls (2019) (0)
Preliminary fMRI results exploring brain activity in a spatial navigation task in schizophrenia, Alzheimer's Disease, and healthy controls (2019) (0)
S.18.04 Early-onset psychotic patients growing up: clinical, imaging and neuropsychological findings (2008) (0)
P.1.e.035 Combined voxel-based morphometry and region of interest methods for studying the hippocampus in Asperger syndrome: preliminary findings (2011) (0)
Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. (2022) (0)
fMRI study of math-gifted adolescents and controls while performing the Raven Progressive Matrices task (2009) (0)
BASELINE ANTIOXIDANT STATUS IS ASSOCIATED WITH 1-AND 2-YEAR FUNCTIONAL OUTCOME IN EARLY-ONSET SCHIZOPHRENIA (2015) (0)
University of California Performance Skills Assessment--Spanish Version (2014) (0)
ONE YEAR FOLLOW-UP LONGITUDINAL STUDY WITH A LARGE SAMPLE OF ANTIPSYCHOTIC-NAIVE CHILDREN AND ADOLESCENTS EXPOSED TO ANTIPSYCHOTICS (2012) (0)
Suicidality: Treatment Occurring in Paediatrics Risk Factors Scale (2020) (0)
T25. THE RELATIONSHIP BETWEEN AGE AT FIRST-EPISODE AND LONGITUDINAL CORTICAL CHANGES IN FIRST-EPISODE PSYCHOSIS: A TWO-YEAR LONGITUDINAL STUDY IN AN ADOLESCENT AND ADULT-ONSET COHORT (2020) (0)
P.4.02 Localized gray matter deficits in adolescents with first-episode psychosis (2007) (0)
Physical and mental health impact of COVID-19 on children, adolescents, and their families (2022) (0)
Behavioral Neurology & Neuropsychiatry: Assessment for subtle neurological signs (2013) (0)
P.3.b.005 Oxidative stress at the first psychotic episode: long-term implications (2013) (0)
Stratification and prediction of remission in first-episode psychosis patients OPTIMISE (2019) (0)
Psychopathology in Children and Adolescents with ASD Without Mental Retardation (2013) (0)
P.7.d.020 Development and validation of a scale for children and adolescents to assess medication related suicidality (2013) (0)
F19. TELOMERE SHORTENING IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A 12-MONTH FOLLOW-UP STUDY (2018) (0)
P.7.b.015 Effectiveness of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study (2017) (0)
Prediction of drop-out and functional impairment in recent-onset schizophrenia spectrum disorders (2021) (0)
P.069 Preliminary results from a comparison of facial emotion recognition in schizophrenia and Alzheimer's Disease, and relationship with social withdrawal (2019) (0)
P.3.d.031 The appropriate pharmacological management of recent-onset schizophrenia: an international panel study using the RAND/UCLA methodology (2016) (0)
De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia (2020) (0)
Neurological signs predict neuropsychological function in schizophrenia (1998) (0)
P.1.e.036 White matter microstructure in Asperger syndrome patients compared with healthy controls (2011) (0)
T30. ASSESSING SHARED VULNERABILITY AND SEX DIFFERENCES IN PSYCHOTIC DISORDERS USING POLYGENIC SCORING (2022) (0)
P.3.02 Metabolic side effects with second generation antipsychotics in antipsychotic-naive adolescents (2007) (0)
University of Groningen Development and psychometric properties of the Suicidality (2017) (0)
PRISM Clinical Study: Preliminary Analysis of EEG Biomarkers in a Sample of the Study Patient Population (2018) (0)
[Antidepressant drugs in the treatment of tension-type headache]. (2008) (0)
P.3.023 Metabolic risk after six months of treatment with second-generation antipsychotics in antipsyehotic-naïve children and adolescents (2012) (0)
Age at first episode modulates progressive cortical thinning in individuals with psychosis (2018) (0)
S80. CHILDHOOD TRAUMA AND SOCIAL COGNITION IN DELUSIONAL PSYCHOSES (2020) (0)
P0199 - A simulation model to estimate the coronary heart disease risk in schizophrenic patients treated with second-generation-antipsychotic drugs: A Spanish perspective (2008) (0)
ANALYSIS OF DE NOVO COPY NUMBER VARIATIONS IN A LARGE, NEW SCHIZOPHRENIA SAMPLE (2017) (0)
P.1.g.019 Glutathione levels at baseline as a predictive biomarker for cognitive functioning at two years follow-up in early onset psychosis (2012) (0)
Report of the 3rd European Brain Policy Forum (2011) (0)
NEGATIVE SYMPTOMS AND SOCIAL COGNITION IN SCHIZOPHRENIA: NEURAL CIRCUITRY, FUNCTIONAL OUTCOMES, AND TREATMENT INNOVATION (2014) (0)
Estimation of the Intelligence Quotient Using Wechsler Intelligence Scales in Children and Adolescents with Asperger Syndrome (2011) (0)
Longitudinal assessment of negative symptoms in early onset first episode psychosis (2019) (0)
Duration of Untreated Psychosis and Cognitive Functioning in First-Episode Psychosis: A Systematic Review and Meta-Analysis (2016) (0)
Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case–control study (2023) (0)
Delphi Panel on the Dimensions and Assessment of Functional Recovery in First-Episode and Early-Phase Schizophrenia Patients (2023) (0)
S0033291719002794jra 2702..2710 (2021) (0)
Experience with the treatment of first episode of schizophrenia: functional outcome (2006) (0)
A integral treatment for attention deficit hyperactivity disorder in Europe Un tratamiento integral para el trastorno por déficit de atención e hiperactividad en toda Europa (2015) (0)
Longitudinal Allometry of Sulcal Morphology in Health and Schizophrenia (2021) (0)
DNA METHYLATION IN EXTREMELY PRETERM BIRTH: RELATIONSHIPS WITH NEURODEVELOPMENT, PSYCHIATRIC DISORDERS AND NEONATAL ACCELERATED AGING (2022) (0)
COGNITIVE PERFORMANCE AND CANNABIS USE IN CHILDREN AND ADOLESCENTES WITH FIRST EPISODE OF PSYCHOSIS (2008) (0)
1657 – Component Structure Of The Positive And Negative Syndrome Scale (panss) In Patients With Schizophrenia Spectrum Disorders And Predominantly Negative Syndrome (2013) (0)
Pilot study of an online intervention for young people with a first psychotic episode: Thinkapp (2022) (0)
COGNITIVEFUNCTIONINGAND CLINICAL SEVERITY AND DRUGATTITUDE IN PSYCHOTIC PATIENTS: RESULTS OF THE CLAMORS STUDY (2008) (0)
Evaluating the tendencies of community practitioners who actively practice in child and adolescent psychiatry to diagnose and treat DSM-5 attenuated psychotic syndrome (2021) (0)
P.1.e.017 Lateral ventricle volume is related to lipid peroxidation in male patients with first episode psychosis (2007) (0)
Use of multiple Polygenic Risk Scores for distinguishing Schizophrenia-spectrum disorder and Affective psychosis categories; the EUGEI study (2021) (0)
Poster #63 CHANGES IN LEPTIN, ADIPONECTIN AND GHRELIN IN ANTIPSYCHOTIC- NAIVE ADOLESCENTS TAKING SECOND-GENERATION ANTIPSYCHOTICS: COMPARATIVE EFFECTS IN PATIENTS WITH PSYCHOTIC AND NONPSYCHOTIC DISORDERS (2012) (0)
Original Article Neurological soft signs in juvenile patients with Asperger syndrome, early-onset psychosis, and healthy controls (2010) (0)
Predictors of number and severity of violence episodes in a one-year follow-up schizophrenia sample (2003) (0)
Development and validation of predictive model for a diagnosis of first episode psychosis using the multinational EU-GEI case-control study and modern statistical learning methods (2023) (0)
Prevalence of the metabolic syndrome (MS) in psychotic patients using two proposed NCEP-ATP-III definitions: Results from the clamors study (2007) (0)
Pushing forward public mental health agenda and promotion of mental health (2023) (0)
P.7.e.001 Oxidative stress and brain volume in early onset psychosis: role of glutathione levels in progressive loss of cortical grey matter (2011) (0)
S17.02 Structural findings in neuropsychiatric disorders: The role of stress (2000) (0)
Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations (2023) (0)
Development and initial validation of a suicidality scale for children and adolescents (2013) (0)
Poster #200 INSULIN-RESISTANCE AND METABOLIC DISTURBANCES RELATED TO SECOND-GENERATION ANTIPSYCHOTICS IN A SAMPLE OF TREATMENT-NAIVE ADOLESCENTS COMPARED TO ADULTS (2012) (0)
THALAMUS VOLUME AND SHAPE IN MALE ADOLESCENTS WITH EARLY-ONSET FIRST-EPISODE PSYCHOSIS (2010) (0)
S.07.08 Localized gray matter deficits in adolescents with first-episode psychosis (2007) (0)
S107. RANDOMIZED CONTROL TRIAL OF A MOBILE APP-BASED INTERVENTION FOR ADOLESCENTS WITH FIRST-EPISODE PSYCHOSIS: THE THINK APP (2020) (0)
Development and psychometric properties of the Suicidality (2016) (0)
P.1.e.006 Differential brain changes in males with early-onset psychotic disorders by diagnosis (2010) (0)
Cómo la Bioestratigrafía de Foraminíferos “On-site” Está Ayudando a ECOPETROL a Ahorrar Dinero y Perforar Mejores Pozos? El Caso del Pozo González-1 [PAPER IN SPANISH] How Well On-Site Foraminifera Biostratigraphy is Helping ECOPETROL to Save Money and D (2006) (0)
Neurological soft signs in juvenile patients with Asperger syndrome , early-onset psychosis , and healthy controlseip (2010) (0)
La humanización en los planes de salud mental en España (2021) (0)
P0120 - Oxidative cell damage is related to the enlargement of the lateral ventricles in children and adolescents with first episode schizophrenia (2008) (0)
Proyecto de fábrica para tratar minerales de plomo con algo de cobre, zinc y hierro (0)
Efficacy of a web-enabled, school-based, preventative intervention on bullying prevalence and mental health in children and adolescents (2020) (0)
Calculation of Cost of Quality and No Quality (2010) (0)
Delphi Panel on the Relationship Between Long-Acting Injectable Antipsychotics and Longer-Term Functional Recovery in First-Episode and Early-Phase Schizophrenia Patients (2023) (0)
T117. PROMINENT AND PERSISTENT AUTISTIC TRAITS ARE ASSOCIATED WITH EARLY NON-REMISSION IN FIRST-EPISODE SCHIZOPHRENIA (2020) (0)
Weight and metabolic risk associated with second-generation antipsychotics in antipsychotic-naïve children and adolescents: A 12 month follow-up study (2019) (0)
S84LONELINESS AND SCHIZOPHRENIA: COMMON VARIATION AND CAUSALITY (2019) (0)
Characterization and prodromal symptoms in early-onset bipolar spectrum disorder (2019) (0)
ACCELERATED CORTICAL THINNING IN SCHIZOPHRENIA IS ASSOCIATED WITH RARE AND COMMON PREDISPOSING VARIATION TO SCHIZOPHRENIA AND OTHER PSYCHIATRIC DISORDERS (2022) (0)
P.1.021 Longitudinal changes of N-acetyl-aspartate in early onset psychosis (2012) (0)
S0033291720003748jra 1910..1922 (2022) (0)
F133. A LONGITUDINAL COMPARISON OF TWO NEUROCOGNITIVE ASSESSMENT PACKAGES IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY VOLUNTEERS: TIME EFFECTS ON NEUROPSYCHOLOGICAL PERFORMANCE AND ITS RELATION TO FUNCTIONAL OUTCOME (2019) (0)
E.07.02 Clinical use of psychotropic drugs in youth – interests and pitfalls (2013) (0)
Needs of People with Schizophrenia/Psychosis and their Caregivers: A Large Scale Survey (2017) (0)
S0033291720002111jra 476..484 (2022) (0)
Patient care, right to information and consent for minors in situations of parental conflict. Clinical guidelines in the context of Spanish legislation (2021) (0)
Review: depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia (2011) (0)
Suicidality: Treatment Occurring in Paediatrics Resilience Factors Scale (2020) (0)
Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders. (2022) (0)
S95. DIFFERENCES IN LIFETIME PATTERNS OF PSYCHOSTIMULANTS AND THEIR IMPACT ON THE PROPORTION OF PATIENTS WITH FIRST-EPISODE PSYCHOSIS ATTRIBUTABLE TO PSYCHOSTIMULANTS USE ACROSS EUROPE (2020) (0)
O3.1. ASSOCIATION OF EXTENT OF CANNABIS USE AND ACUTE INTOXICATION EXPERIENCES IN A MULTI-NATIONAL SAMPLE OF FIRST EPISODE PSYCHOSIS PATIENTS AND CONTROLS (2019) (0)
P.7.b.017 Premorbid to post-morbid functional adjustment course in adolescents after a first episode psychosis (2014) (0)
P.3.b.013 Adolescents with family history of psychosis and the effect of family environment on the antioxidant defense system (2015) (0)
Reviewers for The American Journal of Psychiatry. (2017) (0)
COMT AND DRD3, BUT NOT DRD2, GENOTYPE AFFECT SOFT NEUROLOGICAL SIGNS IN HEALTHY AND FIRST-EPISODE PSYCHOSIS ADOLESCENTS (2008) (0)
EPA volume 65 issue S1 Front cover and matter (2022) (0)
P.3.e.015 Impact of smoking tobacco on healthy life-style habits and 10-year cardiovascular risk in schizophrenia disorders (2009) (0)
Methodologic and Reporting Issues in Published Meta-analysis-Reply. (2021) (0)
WEIGHT GAIN AND METABOLIC CHANGES AFTER SIX MONTHS OF TREATMENT WITH SECOND-GENERATION ANTIPSYCHOTICS IN ANTIPSYCHOTIC-NAÏVE PEDIATRIC AND ADULT PATIENTS (2014) (0)
[15th world congress of psychiatry]. (2011) (0)
P.7.b.001 Prefrontal N-acetyl-aspartate and cognition in adolescents with first-episode psychosis (2006) (0)
Neighborhood Vulnerability and Disability in First Episode of Psychosis: A Multilevel Study. (2023) (0)
Poster #254 SEX DIFFERENCES IN BASAL AND LONGITUDINAL BRAIN CHANGES IN EARLY ONSET PSYCHOSIS (2012) (0)
Analyses of de novo and common alleles implicate rare missense variants in SLC6A1 in schizophrenia (2019) (0)
Cognitive performance in individuals with a first psychotic episode according to age at onset of psychotic symptoms and premorbid intelligence quotient (2023) (0)
P.7.f.002 The affective dimension of early-onset first episode of psychosis (2014) (0)
Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis (2022) (0)
Baseline, Two-year, and Five-year Follow-up of Children and Adolescents with First-episode Psychosis: A Spanish Cohort (2017) (0)
W76. DECIPHERING THE DYNAMIC ROLE OF MIR-137 TARGETOME IN SCHIZOPHRENIA: TEMPORAL PROFILING AND COMORBIDITY WITH PSYCHIATRIC DISORDERS (2021) (0)
P.7.d.010 Liver-function tests in children and adolescents on antipsychotics: a one-year follow-up study (2016) (0)
Mapping the Thalamus in Adolescents with First Episode Psychosis (2009) (0)
S0033291721000453jra 3668..3676 (2022) (0)
P.7.e.004 Prefrontal cortex N-acetyl-aspartate in early-onset psychosis: cognitive correlates, course and predictive value (2007) (0)
Trends in utilisation of hypnotics among Scandinavian young people (2021) (0)
Emotion recognition profiles in clusters of youth based on levels of callous-unemotional traits and reactive and proactive aggression. (2022) (0)
109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis (2018) (0)
O5.6. REMISSION FROM ANTIPSYCHOTIC TREATMENT IN FIRST EPISODE PSYCHOSIS RELATED TO LONGITUDINAL CHANGES IN BRAIN GLUTAMATE LEVELS (2019) (0)
ANTIPSYCHOTICS EFFECTS ON AUDITORY SENSORY GATING IN SCHIZOPHRENIA (2008) (0)
JAMA Psychiatry Peer Reviewer List. (2017) (0)
P50 AUDITORY EVOKED POTENTIAL IN SCHIZOPHRENIA WITH DEFICIT SYNDROME (2008) (0)
P.2.103 Subjective response to new antipsychotics (1997) (0)
P.3.c.042 Psychopathology and coronary heart disease (CHD) in psychotic patients with and without deficit: the Clamors study (2007) (0)
Preventing mental disorders and promoting mental health in the workplace (2022) (0)
Prevalence of Metabolic Syndrome and Coronary Heart Disease Risk in Patients with Schizoaffective Disorder: Clamors Study (2009) (0)
Impact of the COVID-19 pandemic on the mental health of the general population and health care workers (2023) (0)
P.3.c.050 Psychopathology and metabolic syndrome (MS) in psychotic patients: the CLAMORS study (2006) (0)
P.2.129 Safety and toleraty of anti psychotics inchildren and adolescents: Preliminary results of a longitudinal study (2004) (0)
Primary prevention in psychiatry is not science fiction (2022) (0)
P.3.b.009 A longitudinal approach to the influence of oxidative stress in cognition in affective and non-affective psychosis (2014) (0)
P.7.f.005 Development and initial validation of a suicidality scale for children and adolescents (2013) (0)
P.1.e.038 Differences in corpus callosum composition between Asperger syndrome and healthy adolescents: a tractography study (2011) (0)
P.3.14 Early subjective response to antipsychotics: relationship with cognition and treatment adherence in adolescent psychosis (2007) (0)
Author Correction: Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets (2021) (0)
YRP.01 Neurological signs in schizophrenia: trait markers of brain dysfunction (2002) (0)
Genetic variation in dysbindin gene influences both the risk for functional psychosis and the cognitive functioning in a Spanish family based study (2011) (0)
The other side of bipolar disorder. (2014) (0)
P.3.012 Predictors of second-generation antipsychotic-induced weight gain: a longitudinal study on antipsychotic-naive patients (2014) (0)
Oxytocin Exposure in Labor and its Relationship with Cognitive Impairment and the Genetic Architecture of Autism (2022) (0)
EPA-0882 - Prediction of Diagnosis of Early-Onset Schizophrenia Spectrum Disorders Using Support Vector Machines (2014) (0)
Autism Spectrum Disorder: Does Neuroimaging Support the DSM-5 Proposal for a Symptom Dyad? A Systematic Review of Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging Studies (2011) (0)
[Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents]. (2010) (0)
P.7.a.012 Dyskinesia in naïve children and adolescents treated with olanzapine, risperidone and quetiapine: three months follow up (2010) (0)
P.577 ADVANCE: phase 2, randomised, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with negative symptoms of schizophrenia (2020) (0)
Functional dissociations between prefrontal and parietal cortex during task switching: A combined fMRI and TMS study (2022) (0)
P.3.b.034 Cannabis, cognition and family history in first episode psychotic patients (2016) (0)
700 Prediction of violence in schizophrenic inpatients (1997) (0)
Atención a menores con progenitores en conflicto en materia de información y consentimiento relativos a la salud de los hijos. Protocolo asistencial en el contexto de la legislación vigente (2020) (0)
Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-invasive brain stimulation as a new Super-subspecialty (2021) (0)
Analysis of common genetic variation across targets of microRNAs dysregulated both in ASD and epilepsy reveals negative correlation (2023) (0)
17.2 NEGATIVE SYMPTOMS IN THE OPTiMISE COHORT: PREDICTION OF SHORT-TERM REMISSION STATE AND ASSOCIATION WITH PSYCHOSOCIAL FUNCTIONING (2019) (0)
Diagnostic stability of early-onset psychosis over a two-year follow-up (2007) (0)
EPA-0863 - Progression of Changes in Brain Structure and Executive Functions in Children and Adolescents with First-Episode Psychosis (2014) (0)
[Report of the 3(rd) European Brain Policy Forum]. (2011) (0)
EARLY ONSET PSYCHOSIS: LONGITUDINAL BRAIN CHANGES AT TWO YEARS FOLLOW-UP (2010) (0)
Evaluation of the continuation of care between psychiatric hospitalization units and the outpatient clinics in the community. (2005) (0)
P.3.d.017 Predictors of multiple treatment failure of antipsychotics in early-onset psychosis (2016) (0)
P.7.c.006 Antipsychotic drugs in children and adolescents: QTc interval elongation (2006) (0)
Poster #T205 TRAJECTORIES OF NEUROCOGNITIVE FUNCTIONING ACCORDING TO CANNABIS USE PATTERN IN CHILDREN AND ADOLESCENTS WITH FIRST EPISODE PSYCHOSIS: A 2-YEAR FOLLOW-UP STUDY (2014) (0)
P.7.b.013 Neural integrity and cognitive function in early onset psychosis: a longitudinal proton magnetic resonance spectroscopy (H-MRS) study (2014) (0)
Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis-findings from the EU-GEI study. (2023) (0)
P.7.b.004 Influence of duration of untreated psychosis (DUP) on functional outcome in youth with first episode psychosis: a 2-year longitudinal study (2013) (0)
P.630 Neurocognition for the classification of first episode schizophrenia, unaffected family members and healthy controls: A machine learning study (2019) (0)
Poster #40 LONGITUDINAL CHANGE IN LEVELS OF N-ACETYL-ASPARTATE IN EARLY ONSET PSYCHOSIS AND HEALTHY CONTROLS (2012) (0)
S2045796020000943jra 1..10 (2020) (0)
Cognitive Efﬁcacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis (2011) (0)
Poster #S254 INFANCY-TO-ADOLESCENCE FUNCTIONAL DETERIORATION IN EARLY ONSET PSYCHOSIS: ARE THERE DIFFERENCES BETWEEN SCHIZOPHRENIA AND AFFECTIVE PSYCHOSIS? (2014) (0)
P.7.a.005 Antipsychotic metabolic effects in bipolar youth: comparison with other psychotic and non-psychotic diagnoses (2010) (0)
S.13.011 Adherence to a single disease paradigm is not the way to move forward in the treatment of schizophrenia (2013) (0)
Negative symptoms predict functional outcome of early-onset psychosis (2007) (0)
FRONTAL CORTICAL THICKNESS IS ASSOCIATED WITH CLINICAL IMPROVEMENT OF NEGATIVE SYMPTOMS IN MALE ADOLESCENTS WITH EARLY-ONSET FIRST-EPISODE PSYCHOSIS (2010) (0)
C.10.02 Treating mania and managing long-term treatment of bipolar disorder (2009) (0)
T24. CHANGES IN TELOMERE LENGTH IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A 12-MONTHS FOLLOW-UP STUDY (2020) (0)
F20. THINK APP: A MOBILE APP–BASED INTERVENTION FOR ADOLESCENTS WITH FIRST-EPISODE PSYCHOSIS (2019) (0)
Publisher Correction: Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder (2020) (0)
Poster #T199 WORKING MEMORY AND VISUAL MEMORY DEFICIT IN CHILDREN OFFSPRING OF SCHIZOPHRENIA PATIENTS (2014) (0)
P.7.c.007 Insulin resistance and metabolic risk related to second-generation antipsychotics in antipsychotic-naïve pediatric and adult patients (2012) (0)
COGNITIVEFUNCTIONINGAND PHYSICALHEALTH IN PSYCHOTIC PATIENTS: RESULTS OF THE CLAMORS STUDY (2008) (0)
P.2.102 Practical recommendations for the use of risperidone (1997) (0)
Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia (2022) (0)
S.17.02 Safety and tolerability of antipsychotics in children and adolescents (2006) (0)
P.231 Social withdrawal levels influence cerebellar activity during anticipation of social rewards: a trans-diagnostic result (2020) (0)
Poster #249 COGNITIVE PERFORMANCE IN CANNABIS-USING ADOLESCENTS WITH A FIRST EPISODE OF PSYCHOSIS (2012) (0)
Factors associated to persistence of negative symptoms in psychotic patients: Results from the CLAMORS study (2007) (0)
P.3.e.01l Tobacco smoking and schizophrenia spectrum disorders in the CLAMORS study: a case-control analysis in the Spanish context (2009) (0)
Correction to: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey (2020) (0)
Neurobiological susbtrates in deficit and non deficit schizophrenia (2011) (0)
Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome (2020) (0)

This paper list is powered by the following services:

Other Resources About Celso Arango

en.wikipedia.org

What Schools Are Affiliated With Celso Arango?

Celso Arango is affiliated with the following schools:

University of Oviedo
Complutense University of Madrid
University of Manchester